An Open Non-comparative Clinical Trial of the Pharmacokinetics, Safety and Tolerability of VLT-015, Tablets, 100 mg (Valentech LLC) With Single and Multiple Use in Patients With Schizophrenia
Latest Information Update: 23 Aug 2024
At a glance
- Drugs VLT-015 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Valentech
Most Recent Events
- 21 Aug 2024 Status changed from recruiting to completed.
- 30 Aug 2022 New trial record